Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells

Cancer

Volumn 97, Issue 8, 2003, Pages 1955-1962

  Utermark, Tamara ^a   Alekov, Alexi ^a   Lerche, Holger ^a   Abramowski, Vincent ^b   Giovannini, Marco ^b   Hanemann, Clemens Oliver ^a  

^a UNIVERSITY OF ULM   (Germany)

^b FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Cytochrome P450 2D6; Human malignant mesothelioma; K+ outward current; Neurofibromatosis type 2; Proliferation; Quinidine; Schwannoma

Indexed keywords

BROXURIDINE; CYTOCHROME P450 2D6; MERLIN; POTASSIUM ION; QUINIDINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GENETICS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; FLUORESCENCE ACTIVATED CELL SORTING; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MITOSIS INHIBITION; NEUROFIBROMATOSIS; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL;

BLOTTING, WESTERN; BROMODEOXYURIDINE; CELL DIVISION; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; ENZYME INHIBITORS; HUMANS; IMMUNOENZYME TECHNIQUES; MESOTHELIOMA; NEOPLASMS, MESOTHELIAL; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; PATCH-CLAMP TECHNIQUES; POLYMERASE CHAIN REACTION; QUINIDINE; SCHWANN CELLS; TUMOR CELLS, CULTURED;

EID: 0345270393     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11275     Document Type: Article

References (32)

1. Hagemeijer A, Versnel MA, Van Drunen E, et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet. 1990;47:1-28.
2. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in lp, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 1993;53:4349-4355.
3. Bjorkqvist AM, Tammilehto L, Nordling S, et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer. 1998;77:260-269.
4. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas (see comments). Proc Natl Acad Sci USA. 1995;92:10854-10858.
5. Sekido Y, Pass HI, Bader S, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55:1227-1231.
6. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer. 1999;24:238-242.
7. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane organizing protein causes neurofibromatosis type 2. Nature. 1993;363:515-521.
8. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell. 1993;75:791-800.
9. Rosenbaum C, Kamleiter M, Grafe P, et al. Enhanced proliferation and potassium conductance of Schwann cells isolated from NF2 schwannomas can be reduced by quinidine. Neurobiol Dis. 2000;7:483-491.
10. Kamleiter M, Hanemann CO, Kluwe L, et al. Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells. Glia. 1998;24:313-322.
11. Dubois JM, Rouzaire Dubois B. Role of potassium channels in mitogenesis. Prog Biophys Mol Biol. 1993;59:1-21.
12. + channel block-induced mammalian neuroblastoma cell swelling: a possible mechanism to influence proliferation. J Physiol. 1998;510:93-102.
13. + channels in cell proliferation. NIPS. 1994;9:105-110.
14. Wonderlin WF, Strobl JS. Potassium channels, proliferation and G1 progression. J Membr Biol. 1996;154:91-107.
15. Konishi T. Voltage-dependent potassium channels in mouse Schwann cells. J Physiol. 1989;411:115-130.
16. Wilson GF, Chiu SY. Mitogenic factors regulate ion channels in Schwann cells cultured from newborn rat sciatic nerve. J Physiol. 1993;470:501-520.
17. Chiu SY, Wilson GF. The role of potassium channels in Schwann cell proliferation in Wallerian degeneration of explant rabbit sciatic nerves. J Physiol. 1989;408:199-222.
18. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis. 1998;5:55-64.
19. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human schwannoma cells. Oncogene. 1998;16:2195-2209.
20. Wundrack I, Sasiadek M, Blin N. Debrisoquine hydroxylase gene polymorphism in neurofibromatosis type 1. Anticancer Res. 1997;17:4515-4517.
21. Deguen B, Goutebroze L, Giovannini M, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer. 1998;77:554-560.
22. Zeng L, Fleury-Feith J, Monnet I, Boutin C, Bignon J, Jaurand MC. Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol. 1994;25:227-234.
23. Hanemann CO, Rosenbaum C, Kupfer S, Wosch S, Stoegbauer F, Mueller HW. Improved culture methods to expand Schwann cells with altered growth behaviour from CMT1A patients. Glia. 1998;23:89-98.
24. 2+-activated K+ channels in human meningioma cells. J Membr Biol. 2000;175:25-33.
25. Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Mueller HW, Hanemann CO. Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients. Neurobiol Dis. 1998;5:55-64.
26. Neber D, Gonzales F. P450 genes: structure, evolution, regulation. Ann Rev Biochem. 1987;56:945-993.
27. Crespi C, Penman B, Gelboin EI, Gonzales F. A tabacco smoke-derived nitrosamine is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 1991;12:1197-1201.
28. Neber D. Growth signal pathways. Nature. 1990;347:709-710.
29. Gough AC, Miles JS, Spurr NK, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature. 1990;347:773-776.
30. Smith CA, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992;339:1375-1377.
31. Broly F, Marez D, Sabbagh N. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics. 1995;5:373-384.
32. Horita K, Yamaguchi A, Hirose K, et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem. 2001;45:73-84.